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Abstract
Introduction: The prevention of fragility fractures in patients with sarcoidosis is a serious concern and the potential
risk of hypercalcemia limits vitamin D and calcium supplementation. The objective of this study was to evaluate the
risk factors for low bone mineral density (BMD) and fractures in sarcoidosis. In particular, we aimed to determine
the link among bone fragility and calcium and vitamin D metabolism in this population.
Methods: We performed a cross-sectional analysis on 142 consecutive patients with histologically proven sarcoidosis.
BMD and prevalence of vertebral fractures on X-rays were assessed and the association with potential risk factors was
studied by regression analysis.
Results: Fragility fractures occurred in 23.5% of patients, despite a normal mean BMD in the study population. In a
multivariate analysis, low dietary calcium, fracture, age, gender and menopause were associated with increased risk of
low BMD. Low dietary calcium, high current corticosteroid dose and low creatinine clearance were associated with
increased risk of fracture. Serum 25(OH)D between 10 and 20 ng/ml was significantly associated with higher BMD.
Conversely, values greater than 20 ng/ml were associated with increased risk of fracture. Serum 25(OH)D level was
inversely correlated with disease activity. Of note, vitamin D supplements increased serum 25(OH)D in a dose-dependent
manner but had no effect on serum calcium level.
Conclusions: Sarcoidosis patients have a high risk of fracture despite not having a lowered BMD suggesting that other
independent factors are involved. Current corticosteroid dose, low dietary calcium and serum 25(OH)D levels are
associated with bone fragility. In sarcoidosis, calcium and vitamin D supplementation might be warranted, but desirable
25(OH)D serum levels might be lower than those advised for the general population.
Introduction
Sarcoidosis is a multifaceted granulomatous disease ran-
ging from regressive localized forms to chronic systemic
involvement. The risk of fracture in sarcoidosis has not
been clearly evaluated although most patients may present
risk factors of osteoporosis. Like in other chronic diseases,
as rheumatoid arthritis (RA) [1] or spondyloarthritis [2],
both corticosteroid (CS) use and systemic inflammation
could promote bone loss in sarcoidosis.
Disorders of calcium and vitamin D metabolism could
also interfere with bone mineral density in sarcoidosis.
Extra renal synthesis of the active form of vitamin D (1,25
(OH)2D) takes place inside the granulomas under the in-
fluence of 1alpha-hydroxylase. In contrast to the renal en-
zyme, the 1-alpha-hydroxylase expressed by macrophages
is not inhibited by serum 1,25(OH)2D levels; moreover,
the stimulation of the 25(OH)D-24-hydroxylase trans-
forming the 1,25(OH)2D into inactive 24,25(OH)2D is
stimulated only at very high levels of 1,25(OH)2D [3,4].
The resulting high levels of calcitriol could contribute to
increased intestinal absorption of calcium, which might
partly explain the hypercalcemia sometimes observed in
sarcoidosis. Moreover, sarcoidosis patients are more sensi-
tive than healthy subjects to vitamin D supplements with
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a higher increase in serum calcium after intake [5]. For
these reasons, many experts advise patients to avoid sun
exposure and vitamin D and calcium supplements, with
the potential risk of chronic vitamin D deficiency.
These risks factors are nevertheless balanced by the
fact that the disease evolves generally in young adults, at
lower risk of fracture. Moreover, CS-free remission pe-
riods can be very long, and it was shown that in sarcoid-
osis the effect of CS on bone might be, at least partially,
reversible [6,7]. Few studies with contradictory results
are available in the literature, probably due to limited
sample size and heterogeneous clinical presentation of
included patients. Previous studies using quantitative
computed tomography (QCT) showed a reduction of
bone mineral content (BMC) even in patients not
treated with CS [7,8]. Thereafter, similar results were
found only in lumbar spine BMD of post-menopausal
women [9] or in CS-treated subjects [10-12]. In contrast,
in a four-year longitudinal study, no bone loss was ob-
served even in CS-treated patients despite a high rate of
fracture (38%) observed by vertebral fracture assessment
(VFA) [13]. This suggests that other determinants apart
from BMD are probably involved in fracture risk. So far,
the link between serum 25(OH)D level and BMD has
not been studied in sarcoidosis.
Our objective was to determine the risk factors for
bone fragility evaluated by BMD and fracture prevalence
in sarcoidosis patients and in particular to evaluate the
relationship with vitamin D and calcium metabolism in
a pilot cross-sectional study.
Methods
Study design
We included 142 consecutive patients with sarcoidosis ac-
cording to the criteria retained in the Consensus Confer-
ence ATS/ERS [14], that is, combining clinical, biological
and radiological presentation compatible with diagnosis
and excluding other granulomatous diseases. Among 222
patients attending pneumonology consultation or day-
hospital during the inclusion period, 74 were excluded be-
cause they did not meet inclusion criteria and 6 refused to
participate in the study. All 142 remaining included pa-
tients presented documented histological lesions of granu-
loma without caseous necrosis, in at least one site of
biopsy. Patients with other chronic progressive diseases,
chronic respiratory or renal insufficiency stage IV and V
whose origin was not related to sarcoidosis and those on
diuretics able to interfere with calcium metabolism were
excluded from the study. At inclusion, all patients under-
went clinical examination evaluating the risk factors for
osteoporosis and calcium intake. All patients had bio-
chemical, radiological and BMD assessment.
This study complies with the Declaration of Helsinki
and was approved by the Ethical Committee of France
10 (N° ID RCB 2011-A00202-39). All patients gave their
informed consent prior to their inclusion in the study.
Clinical parameters
For each patient, a questionnaire assessed the following
risk factors for osteoporosis: age, sex, menopausal status,
tobacco and alcohol consumption, body mass index (BMI),
personal or family history of fracture of low energy (defined
as resulting from a fall from standing height or lower; skull,
metacarpal and metatarsal fractures were excluded).
Anti-osteoporotic treatments, current and cumulated
CS dose and vitamin D supplements in the six months
preceding the study were recorded. Dietary calcium intake
was evaluated by the Fardellone auto-questionnaire [15].
The data related to sarcoidosis were also collected: dis-
ease duration, localization (graded from 0 to 6 according to
the degree of severity of each organ involvement), current
flare (at least one active localization or new localization in
the three months preceding the study), number of relapses,
stage of pulmonary involvement (stage 0: normal chest
radiography; stage I: bilateral hilar lymphadenopathy with-
out pulmonary infiltrates; stage II: bilateral hilar lymph-
adenopathy with pulmonary infiltrates; stage III: pulmonary
infiltrates without bilateral hilar lymphadenopathy; stage
IV: end-stage fibrosis, bullae, honeycombing and cavity),
stage of dyspnoea from I to IV according to New York
Heart Association (NYHA) classification.
Biochemical parameters
The serum levels of calcium (corrected with albumin),
phosphate, 25(OH)D (Diasorin radioimmunoassay, Stillwater,
US), 1,25(OH)2D (IDS radioimmunoassay, Frankfurt,
Germany), creatinine, parathyroid hormone (PTH)
(immunometry LIA, Immulite 2000, Puteau, France),
thyroid stimulating hormone (TSH), bone markers: bone
alkaline phosphatases (BALP) (ELISA, reactif microrevue),
C-terminal telopeptide of type I collagen (CTX) (ECLIA/
Cobas-Roche, Switzerland), osteocalcin (immunometry
TRACES, Kryptor), 24-hour urinary calcium, phosphate
and creatinine, were gathered. Other parameters: erythro-
cyte sedimentation rate (ESR), C-reactive protein (CRP),
serum angiotensin-converting enzyme (ACE) level, blood
count and serum albumin level were also gathered.
Imaging parameters
Radiographs of thoracic and lumbar spine (face and profile)
were carried out. Assessment of vertebral fractures was in-
dependently performed by both a radiologist (NN) and a
rheumatologist (NSK) according to the semi-quantitative
method of Genant [16] and their respective results were
blinded during assessment. Inter-rater reliability was good
K = 0.78, 95% CI (0.63 to 0.93). Vertebral fracture was de-
fined by reduced height loss above 20% of the mean, pos-
terior or anterior wall.
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BMD was measured by dual X-ray absorptiometry
(DXA Lunar Prodigy, GE Healthcare) at the lumbar spine
and the total hip. Osteopenia and osteoporosis were de-
fined by a-1SD < T-score < -2.5 SD and T-score ≤ -2.5 SD,
respectively. Low BMD was defined by a T-score < -1 SD
(osteopenia or osteoporosis).
Statistical analysis
Data are summarized as the mean and standard devi-
ation for continuous data and frequency for categorical
data. A logistic regression model was used to identify
factors associated with low BMD (defined as a T-Score
lower than -1 SD) and risk of fracture. 25(OH)D was
grouped in three categories as retained by the Institute
of Medecine [17]: ≤10 ng/ml (deficiency), 10 to 20 ng/ml
(insufficiency) and ≥20 ng/ml (desirable). All factors with
P <0.20 at univariate analysis were included in a multiple
logistic regression model with backward selection. Age,
gender and menopause were grouped together to avoid
a colinearity problem in multivariate analysis. Serum 25
(OH)D and calcium levels according to different criteria
were compared with the Mann-Whitney U-test, with a
Bonferroni correction for multiple tests. The associa-
tions between the continuous factors were determined
with Spearman’s correlation coefficients. All tests were
two-sided at a 0.05 significance level. Analyses were car-
ried out using R statistical software version 2.14.1.
Results
Clinical characteristics of the patients
One hundred forty two patients, 80 women (51 meno-
paused) and 62 men, were included. Eighty-five patients
were Caucasians, 54 Caribbeans and 3 Indians. Mean age
was 51.6 ± 11.6 years and BMI 27.5 ± 5.4. Mean disease
duration was 9.5 ± 7.1 years and 104 patients had pre-
sented more than one relapse; 21/137 patients experi-
enced a low energy fracture before inclusion. Eighty-eight
patients were receiving CS treatment at the time of the
study (mean dose 12.4 ± 11.8 mg/d of prednisone equiva-
lent), 28 patients had never received CS, 45 interrupted
CS treatment for at least six months. The mean cumulated
CS dose was 27.6 ± 19.9 g of prednisone equivalent.
Thirty-one patients had received vitamin D supplements
in the six months preceding the study (mean dose
181,161 ± 137,430 U) and 15 were on supplementation at
inclusion. Forty-six patients had received a specific bone
treatment before the study (bisphosphonates in the major-
ity) on average for 25.3 ± 26.7 months; 24 were still treated
during the study. The mean daily dietary calcium was
717.2 ± 360 mg (Table 1).
Biochemical parameters of bone metabolism
Biochemical parameters are shown in Table 1. Serum
calcium was within the normal range with no significant
difference between summer (June to August) and winter
(December to February), respectively, with a mean level
of 2.36 ± 0.06 mmol/l vs 2.32 ± 0.1 mmol/l ( P = 0.16).
Only one patient had high serum calcium (>2.6 mmol/L),
(without hypercalciuria) related to a systemic form with
documented bone sarcoidosis lesions. Nine out of 94
patients presented hypercalciuria (24-hour urinary cal-
cium >0.1 mmol/kg).
Serum 25(OH)D levels were low (Figure 1) with a mean
of 14.5 ± 7.61 ng/ml but with normal mean PTH serum
level. The 31 patients who had received vitamin D supple-
ments had significantly higher 25(OH)D but not higher
serum calcium levels vs. those not supplemented and no
significant change in 1,25(OH)2D serum level (Figure 2).
CS-treated or untreated patients did not differ in 25
(OH)D and 1,25(OH)2D serum levels nor in CRP or
ESR (trend toward a lower ESR on CS).
There was no association between bone markers and
BMD value or fracture. However, as expected, CS-treated
patients had significantly lower bone marker serum levels:
(CTX : 372.1 pg/ml with CS vs. 480.6 pg/ml without
CS, P = 0.01; BALP : 30.0 ± 13.5 UI/L vs 33.5 ± 10.8 UI/L,
Table 1 Patients characteristics and biochemical
parameters
Women/men (number of patients) -80/62
Menopausal women (number of patients) 51/80
Age (years) 51.6 ± 11.6
Mean disease duration (years) 9.5 ± 7.1
BMI (mean ± SD) 27.5 ± 5.4
Radiological Stage I/ II/ III/IV/ (number of patients) 15/69/14/41
Dyspnoea Stage NYHA I and II/ NYHA III and IV
(number of patients)
118/45
History of low energy fracture (number of patients) 21
Current CS intake (mean dose): 88 patients 12.4 ± 11.8 mg
Mean cumulative CS dose per patient 27.6 ± 19.9 g
Vitamin D supplements (mean dose) in the six
months before the study: 31 patients
181,161 ± 137,430 U
BP treatment (mean treatment duration) before
study: 46 patients
25.3 ± 26.7 months
Mean serum 25(OH)D level (N >30 ng/ml) 14.5 ± 7.61
Mean serum 1,25(OH)2D level (66 < N <167 pmol/l) 137.4 ± 50.3
Mean serum PTH level (10 < N <70 pmol/l) 45.36 ± 31.4
Mean creatinine clearance (ml/min) 110.7 ± 35.9
Mean serum calcium level (2.2 < N <2.6 mmol/l) 2.35 ± 0.9
Mean ESR (mm/h) 17.6 ± 14.5
Mean CRP (mg/L) 7.0 ± 9.8
Mean ACE (19 < N <41) 51.7
ACE, angiotensin-converting enzyme; BMI, Body mass index; BP, bisphosphonates;
CRP, C-reactive protein; CS, Corticosteroids; ESR, erythrocyte sedimentation rate;
NYHA, New York Heart Association; PTH, parathyroid hormone.
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P <0.05; osteocalcin: 15.5 ± 10.1 ng/ml vs 25.2 ± 13.2 ng/ml,
P <0.001).
Vitamin D supplementation was positively correlated
with serum 25(OH)D (r = 0.38, P <0.001) but not with
serum calcium level.
Serum levels of 25(OH)D show significant but weak in-
verse correlation with disease flares (r = -0.18, P <0.05), the
severity of the pulmonary involvement (r = -0.18, P <0.05),
ACE (r = -0.19, P <0.05) and ESR (r = -0.19, P <0.05). 1,25
(OH)2D serum levels are positively correlated with serum
25(OH)D (r = 0.35, P <0.001) and with no other parameter.
In particular, we did not find correlation between 1,25
(OH)2D serum level and chronicity of the disease (r = -0.08,
P = 0.37) that was found by D Kavathia et al. [18] or the
number of relapses.
Osteoporosis prevalence in sarcoidosis
The mean BMD was normal: Tscore: -0.5 SD at the lum-
bar spine and -0.09 SD at the total hip. However, 34.8%
presented low BMD at the lumbar spine (37 patients
had osteopenia and 11 patients had osteoporosis, re-
spectively) and 24% had osteopenia or osteoporosis at
the hip (24 patients and 9 patients, respectively). On the
whole, 40.15% (55/137) were osteopenic at one skeletal
site at least, and 14.6% (20/137) were osteoporotic.
Figure 1 Distribution of 25(OH)D (A) and 1,25(OH)2D (B) serum level in the study population.
Figure 2 Changes in serum 25(OH)D, calcium and 1,25 (OH) 2D level after vitamin D supplementation. Changes in serum 25(OH)D
(A) calcium (B) and 1,25 (OH) 2D (C) level according to the dose of vitamin D supplementation in the six months that preceded the study.
There is no significant change in calcium and 1,25 (OH) 2D serum level depending on the total amount of vitamin D supplementation.
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A total of 13.6% of the patients (19/139) had at least one
vertebral fracture and 10 patients presented with two or
more vertebral fractures. Overall, 23.5% of patients (32/
136) had at least one vertebral or peripheral fracture.
Risk factors for bone fragility in sarcoidosis
Table 2 shows the odds ratio of low BMD and fractures
at univariate analysis. Low BMD (T-score < -1 SD) is as-
sociated with age, menopause, prevalent fracture, low
dietary calcium intake, cumulative CS dose, long disease
duration, advanced-stage dyspnoea (III or IV), lympho-
penia, high ESR and low creatinine clearance. The pa-
tients with serum levels of 25(OH)D between 10 and
20 ng/ml have the lowest odds of low BMD, whereas the
odds increase when this threshold is exceeded. Fractures
were significantly associated with age, low dietary cal-
cium intake, cumulative and current CS dose, advanced-
stage dyspnoea (III or IV), low creatinine clearance and
low BMD. Of note, 25(OH)D levels exceeding 20 ng/ml
are associated with significantly higher odds of fracture
(Table 2). BMI, ethnicity, type of sarcoidosis involve-
ment, CS-free period duration, smoking, 1,25(OH)2D
serum level, CRP, bone remodelling markers showed no
association with BMD or fracture.
We then assessed factors associated with low BMD
using multivariate analysis (Table 3). Age, prevalent frac-
ture, female gender, menopause, low dietary calcium,
lymphopenia and vitamin D supplementation are associ-
ated with higher odds of low BMD. Again, the patients
with 25(OH)D serum levels between 10 and 20 ng/ml are
at lower risk of low BMD vs. those with levels <10 ng/ml
(reference class), while levels exceeding 20 ng/ml are
associated with a higher risk of fracture. Low dietary
calcium and high CS doses are also associated with a
higher risk of fracture.
The relationship between 25(OH)D serum level and risk
of low BMD in our population, using a generalized addi-
tive model followed a U-shaped curve: patients with
serum 25(OH)D levels between 10 and 20 ng/ml are at
lower risk of low BMD. The relationship between 25(OH)
D and fracture is more linear, but with a steeper slope for
25(OH)D values above 20 ng/ml (Figure 3A, B).
We then evaluated whether history of vitamin D sup-
plementation or BP treatment modified the relationship
between 25(OH)D serum level, low BMD and fracture.
In our sample, vitamin D-supplemented or BP-treated
patients had higher prevalence of bone fragility fracture
(P <0.01) and lower BMD at both the lumbar spine
(P <0.01) and hip (P <0.05) (Table 4).
The relationship between 25(OH)D serum level and
BMD is unmodified if those patients are excluded from
the analysis (interaction between 25(OH)D serum level
and vitamin D supplements or BP treatment, P = 0.71),
(Figure 3C). Conversely, as far as fracture is concerned,
Table 2 Factors associated with low BMD and fracture at univariate analysis
BMD< −1SD Fracture
OR [95% CI] P OR [95% CI] P
Menopause 5.29 [1.83; 15.27] 0.002 2.1 [0.68; 6.53] 0.2
Age, years 1.06 [1.03; 1.1] <0.001 1.09 [1.05; 1.14] <0.001
Calcium intake <500 mg/d 4.28 [1.89; 9.72] <0.001 2.2 [0.93; 5.18] 0.072
Stage NHYA 3 or 4 3.34 [1.3; 8.54] 0.012 3.18 [1.23; 8.2] 0.017
Disease duration 1.05 [1; 1.1] 0.047 1 [0.95; 1.06] 0.9
Cumulative CS dose 1.15 [0.98; 1.36] 0.088 1.2 [0.99; 1.44] 0.059
Current CS treatment 1.68 [0.83; 3.4] 0.15 2.63 [1.08; 6.37] 0.033
Vitamin D supplements 3.82 [1.66; 8.8] 0.002 2.07 [0.87; 4.95] 0.1
BP treatment 3.03 [1.44; 6.36] 0.003 1.83 [0.8; 4.15] 0.15
ESR >10 mm/h 2.49 [1.1; 5.62] 0.028 1.38 [0.55; 3.46 0.5
Lymphocytes >1,000/mm3 0.45 [0.21; 0.94] 0.033 1.19 [0.5; 2.85] 0.7
Creatinine clearance, ml/mn 0.99 [0.98; 1] 0.034 0.97 [0.95; 0.99] <0.001
25(OH)D serum level
25(OH)D ≤10 ng/ml 1 - 1 -
10 < 25(OH)D <20 ng/ml 0.48 [0.21; 1.09] 0.079 1.24 [0.45; 8.23] 0.67
25(OH)D >20 ng/ml 2.00 [0.8; 4.97] 0.13 2.94 [1.05; 8.23] 0.04
Serum PTH level, pmol/l
Fracture/low BMD 4.39 [1.86; 10.37] <0.001 4.39 [1.86; 10.37] <0.001
BMD, bone mineral density; BP, bisphosphonates; CS, Corticosteroids; ESR, erythrocyte sedimentation rate; PTH, parathyroid hormone; NYHA, New York
Heart Association.
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Table 3 Factors associated with low BMD and fracture at multivariate analysis
BMD< −-SD Fracture
OR [95% CI] P OR [95% CI] P
Menopausal female 13.84 [2.28; 84.11] 0.004
Male ≥50 years 12.2 [1.42; 104.71] 0.023
Calcium intake <500 mg/d 3.98 [1.19; 13.25] 0.025 3.5 [1.09; 11.27] 0.036
Vitamin D supplements 12.86 [2.98; 55.53] 0.001
BP treatment 4.6 [1.47; 14.3 ] 0.009
Fracture 3.88 [0.99 ;15.23] 0.052
25(OH)D ≤10 ng/ml 1 - 1 -
10 < 25(OH)D ≤20 ng/ml 0.29 [0.08; 1.06] 0.062 2.05 [0.57; 7.45] 0.274
25(OH)D >20 ng/ml 0.96 [0.25; 3.67] 0.95 3.93 [1.02; 15.17] 0.047
Current CS treatment 3.73 [1.06; 13.16] 0.04
Creatinine clearance 0,97 [0.94; 0.99] 0.002
BMD, Bone mineral density; BP, Bisphosphonate; CS, Corticosteroids. Empty cells correspond to variables not included in the multivariate analysis because they
were not significant at univariate analysis or to variables included in the multivariate analysis but not retained in the final model because they were no longer
significant (for example, age).
Figure 3 Relation between 25(OH)D and low BMD and fracture. Relation between 25(OH)D (ng/ml) and the odds of low BMD (A, C) and
fracture (B, D) with the use of a generalized additive model (GAM) for the totality of patients (A, B) and after exclusion of Vitamin D or BP-treated
patients (C, D) respectively. The relationship between vitamin D levels and the odds of low BMD follows a U-shaped curve (A, C) while the relationship
with fracture risk follows a linear relationship. Shaded areas represent the 95% confidence intervals and the tick marks show the distribution
(with median and interquartile range) of 25(OH)D values. BMD, bone mineral density; BP, bisphosphonates.
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there is a significant interaction between 25(OH)D and
vitamin D and BP treatment (P <0.05), explained by the
low prevalence of fracture in patients with serum levels
of 25(OH)D <10 ng/ml if vitamin D and BP-treated pa-
tients are excluded (Table 4). Nevertheless, even after
exclusion of these patients, the relationship between 25
(OH)D levels and fracture remains linear (Figure 3D).
Discussion
This study is the first that assesses the link between the
metabolism of calcium and vitamin D and the risk of
osteoporosis in a population of patients with sarcoidosis.
We observe that 25(OH)D levels are associated with low
BMD and fracture and might be a risk factor for both.
In addition, we found a high prevalence of fracture con-
trasting with a normal mean BMD in this population.
The results of this study allow us to highlight three sig-
nificant points concerning vitamin D in sarcoidosis.
First, we found a significant association among 25(OH)
D serum level, BMD and risk of fracture. Levels ranging
between 10 and 20 ng/ml are associated with higher BMD
while this association is lost for higher values, which are
conversely associated with higher risk of fracture. These
associations do not seem to be due to vitamin D supple-
ment in patients with lower BMD or higher risk of frac-
ture. In fact, the associations persisted at multivariable
analysis after correction for vitamin D supplementation in
the last six months. Moreover, the exclusion of patients
having received vitamin D or BP supplements to prevent
corticosteroid-induced osteoporosis did not affect the re-
lationship between 25(OH)D and BMD or fracture at gen-
eralized additive model analysis. These data suggest that
excessive vitamin D supplement could be deleterious in
these patients.
This notion might be supported by the results of recent
studies on the general population: Vital D Study [19], a
double-blind, randomized, controlled trial involving 2,317
community-dwelling women (mean age 70 years) ran-
domly assigned to receive either a single oral dose of cho-
lecalciferol 500,000 IU or placebo yearly for three to five
years, found a higher risk of fracture and fall in supple-
mented women in whom baseline 25(OH)D serum level
increased from 19.6 to 48.07 ng/ml. Grimnes et al. [20]
found that excessive vitamin D supplementation (inducing
mean maximum serum level 74 ng/ml) is associated with
lower BMD and decrease of bone remodeling in osteope-
nic post-menopausal women. Finally, Ensrud et al. [21]
found that association between 25(OH)D and frailty status
(a risk factor of fall and fracture) may have a U-shaped
pattern with increasing odds of frailty at the lower
(<20 ng/ml) and higher (≥30 ng/ml) 25(OH)D levels.
In sarcoidosis patients, known to be more sensitive to
vitamin D [5], the optimal range of 25(OH)D levels might
be lower than that desirable for the general population as
it has been described in idiopathic infantile hypercalcemia.
In this rare disease, the presence of CYP24A1 mutation
causes inactivation of 24-hydroxylase and explains the in-
creased sensitivity to vitamin D [22]. In this disease, 25
(OH)D serum must be maintained at low levels to avoid
hypercalcemia.
Even if the biological mechanism of the toxicity of
high vitamin D levels remains speculative [23-25], extra-
renal synthesis of 1.25(OH)2D in sarcoid granuloma
resulting in excessive 1.25(OH)2D levels, could be in-
volved [3]. In our sample, there was a positive correl-
ation between 25(OH)D and 1,25(OH)2D serum levels.
While physiological levels of 1.25(OH)2D inhibit PTH-
dependent bone resorption, higher levels are conversely
known to induce bone resorption. Hamada et al. [26]
found that in female (but not male) CS-free sarcoidosis
patients, 1.25(OH)2D levels were negatively correlated
with lumbar Z-score and serum calcium and positively
correlated with osteocalcin. In our patients, whether
treated with CS or not, we did not find any correlation
between serum 1,25(OH)2D and bone markers apart
from a negative correlation with bone alkaline phosphat-
ase. However, dosing of 1.25(OH)2D is subject to fluctu-
ations [27], and our population was not homogeneous:
the patients had variable forms of the disease and most
of them were on CS. All these factors might have inter-
fered with the results. Nevertheless, consensus exists
that the level of 25(OH)D (precursor of 1,25(OH)2D) is
more stable and more relevant to evaluate vitamin D
status [28]. Hence, 25(OH)D might be better suited to
assess the relationship between vitamin D and both os-
seous and extra-osseous involvement of the disease.
The second point concerning vitamin D is the possible
correlation between low 25(OH)D serum level (and not
Table 4 Prevalence of patients having low BMD (≤1 SD) or at least one prevalent fracture according to 25(OH)D serum
levels
BMD Fracture
All patients No BP or Vitamin D All patients No BP or Vitamin D
25OHD <10 20/46 (43%) 8/29 (27%) 8/46 (17%) 2/27 (7%)
10 < 25OHD <20 15/56 (27%) 5/31 (16%) 11/53 (21%) 8/28 (28%)
25OHD >20 20/33 (61%) 4/7 (57%) 13/34 (38%) 2/7 (28%)
BMD, bone mineral density; BP, bisphosphonates. The results are reported for the whole sample and for those patients that had not received BP treatment or
vitamin D supplementation.
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1.25(OH)2D) and the parameters of disease activity. This
was suggested in other inflammatory diseases, such as
RA, where low 25(OH)D levels were associated with dis-
ease flares [29,30].
The third important point is that patients supple-
mented with vitamin D have significantly higher serum
25(OH)D but not higher serum calcium vs. non-
supplemented patients. Accordingly, Adler et al. [10] did
not find any impact of calcium and vitamin D supple-
mentation on serum or urinary calcium in sarcoidosis
patients.
Overall, our findings suggest that vitamin D supple-
mentation should be considered in sarcoidosis patients
but should probably target a threshold that might be
lower than that advised for the general population. In
addition, low dietary calcium correlated with low BMD
and high risk of fracture support the need for adequate
calcium intake in these patients.
Nevertheless, the risk of hypercalcemia after vitamin
D supplementation reported in other series should lead
to caution [31]. Further studies are needed to better
identify what patient can be safely supplemented in cal-
cium and Vitamin D and at what dose.
We observed a higher prevalence of fracture com-
pared to epidemiological data on healthy adults of the
same age [32]. This prevalence is also close to that
found in young, adult CS-treated patients with other
diseases [33] and to that found by Heijckmann [34] in a
cross-sectional study in sarcoidosis patients. Even if low
BMD was correlated with the risk of fracture, mean
BMD was normal in our study patients, contrasting
with the high prevalence of fracture. This suggests that
other factors than BMD are involved, and must be taken
into account, in the evaluation of global fracture risk in
these patients. Among them, cumulative CS dose, age,
respiratory insufficiency and altered renal function were
all associated with increased risk of fracture at univari-
able analysis.
We did not find any correlation between BMD or frac-
tures and parameters of inflammation but in this study
the average ESR and CRP were low. However, lympho-
cyte count was inversely correlated with BMD at both
univariable and multivariable analysis.
The main study limitations lie in the cross-sectional
and monocentric design, in the lack of a control popula-
tion and the heterogeneity of the disease profile in the
study population. This last point is difficult to prevent to
get a sufficient sample size of patients but the multivari-
ate analysis allows us to identify the main risk factors of
osteoporosis. The main strength is the large sample size
for this disease. These preliminary data need to be con-
firmed in longitudinal studies in particular to verify the
association between the different levels of 25(OH)D and
the risk of fracture or low BMD.
Conclusion
This is the first study that establishes a link between
vitamin D levels and bone mineral density in patients
with sarcoidosis and suggests an optimal threshold of 25
(OH)D in this population. Furthermore, these data sug-
gest that particular risk factors for osteoporosis should
be taken into account for sarcoidosis patients, whose
fracture risk is high and poorly related to BMD.
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